Agenus Inc. — Q1 2012 Form 10-Q
Reporting period: Quarter ended March 31, 2012. Unaudited consolidated financial statements; comparisons are with Q1 2011 unless noted. Agenus is a biotechnology company developing cancer and infectious-disease therapies, including QS-21 adjuvant, Prophage vaccines, and HerpV.
Financial results and liquidity
| Metric | Q1 2012 | Q1 2011 / comparison |
|---|---|---|
| Revenue | $13.4 million | $0.7 million |
| Operating income (loss) | $7.8 million | $(5.0) million |
| Net income (loss) | $6.8 million | $(6.0) million |
| Net income (loss) attributable to common stockholders | $6.6 million; $0.29 per share | $(6.2) million; $(0.33) per share |
| Research and development expense | $2.7 million | $2.8 million |
| General and administrative expense | $2.9 million | $2.9 million |
| Net interest expense | $1.1 million | $0.9 million |
| Net cash provided by (used in) operating activities | $11.3 million | $(4.6) million |
- Revenue and reported profitability were driven mainly by one-time license amendments: $6.5 million recognized from an expanded GSK license and $6.25 million from an exclusive license amendment and royalty-stream buyout with an existing licensee. The company recognized $12.8 million in revenue from these amendments; deferred revenue included $2.5 million related to the GSK agreement. Management cautioned that these payments are not indicative of future results.
- Cash and cash equivalents were $24.6 million at March 31, up $13.8 million from year-end 2011. Total assets were $33.2 million; total current liabilities were $5.5 million. Stockholders’ deficit was $10.6 million.
- Debt outstanding was $37.9 million in principal: $37.5 million of 8% senior secured convertible notes due August 2014 and $0.1 million of 5.25% convertible notes due February 2025. The 2006 Notes are secured by equity in a subsidiary holding important QS-21 and HerpV rights and include restrictive covenants.
- Operating cash flow benefited from the license payments and working-capital changes, including increased deferred revenue; it should not be treated as a recurring cash-generation rate. Net cash burn guidance for 2012, as defined by the company, was $13–16 million.
Business developments, outlook, and risks
- GSK paid $9.0 million under a March 2012 agreement granting an additional license and a five-year first right to negotiate for a potential acquisition of Agenus or certain assets. The agreement provides for additional royalties if a product for the undisclosed indication is commercialized; $2.5 million of the payment is creditable against future manufacturing technology-transfer royalty payments.
- Agenus said existing working capital and estimated proceeds from license, supply, and collaboration agreements were expected to fund liquidity needs into the second half of 2013. This estimate depends on current plans and anticipated proceeds. The company expected to seek additional funding before exhausting available funds and could pursue licensing, renegotiations, asset sales, debt, or equity financing.
- QS-21 was included in approximately 15 partner-developed vaccines in clinical development, four in Phase 3. Agenus anticipated first launches around 2014 and potential royalties thereafter, but outcomes depend on partners’ clinical, regulatory, manufacturing, and commercialization success.
- Prophage G-100 and G-200 were in Phase 2 trials for newly diagnosed and recurrent glioma, respectively. HerpV had completed Phase 1; Agenus planned to initiate a Phase 2 trial in the second half of 2012. Oncophage was approved in Russia for a limited kidney-cancer indication, but sales had been minimal and reimbursement and partner execution remained uncertain.
- Management expected continued significant losses and additional development spending. Clinical and regulatory timelines, costs, efficacy, approvals, commercialization, and future cash inflows were uncertain. The filing warns that inability to raise capital or longer-than-expected losses could threaten continued operations.
- Other material risks include the 2006 Notes’ conversion and security provisions, potential dilution from equity issuance, dependence on collaborators and licensees, manufacturing and supply constraints, competition, intellectual-property limitations (including expiration of the QS-21 composition patent in most territories), and the possibility of inadequate reimbursement. Agenus reported no material pending legal proceedings and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether the reported cash runway remains achievable after excluding one-time license proceeds and considering the stated $13–16 million 2012 net cash burn estimate.
- The full economics and obligations of the GSK and other license amendments, including deferred revenue, royalty terms, and GSK’s first right to negotiate.
- Debt terms, covenant compliance, interest accrual, and the consequences of the 2006 Notes’ security and conversion rights.
- Clinical progress and outcomes for Prophage and HerpV, and whether QS-21 partner programs reach approval and launch on the anticipated schedule.
- Future financing needs, potential share dilution under the at-the-market program, and the availability and terms of additional capital.